2-(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid | 1368392-66-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid
• CAS: 1368392-66-8
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: PNUKFQFAUOLFAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid 、 3-[1-(2S-amino-3-methylbutyl)-3R,4R-dimethyl-4-piperidinyl]phenol 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以257 mg的产率得到N-[(2S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]-3-methylbutan-2-yl]-2-(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetamide
  参考文献：
  名称：

  Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic)

  摘要：

  In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 1) as the first potent and selective K opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist. In the present study, we report the synthesis and in vitro opioid receptor functional antagonism of a number of analogues of 1 using a [S-35]GTP gamma S binding assay. The results from the studies better define the pharmacophore for this class of K opioid receptor antagonist and has identified new potent and selective kappa antagonist. (3R)-7-Hydroxy-N-[(1 S, 2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylbutyl]-1,2,3,4tetrahydroisoquinoline-3-carboxamide (3) with a K-e value of 0.03 nM at the kappa receptor and 100- and 793-fold selectivity relative to the mu and delta receptors was the most potent and selective kappa opioid receptor antagonist identified.

  DOI：

  10.1021/jm701344b
• 作为产物：
  描述：

  (6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid ethyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 2-(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid
  参考文献：
  名称：

  Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic)

  摘要：

  In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 1) as the first potent and selective K opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist. In the present study, we report the synthesis and in vitro opioid receptor functional antagonism of a number of analogues of 1 using a [S-35]GTP gamma S binding assay. The results from the studies better define the pharmacophore for this class of K opioid receptor antagonist and has identified new potent and selective kappa antagonist. (3R)-7-Hydroxy-N-[(1 S, 2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylbutyl]-1,2,3,4tetrahydroisoquinoline-3-carboxamide (3) with a K-e value of 0.03 nM at the kappa receptor and 100- and 793-fold selectivity relative to the mu and delta receptors was the most potent and selective kappa opioid receptor antagonist identified.

  DOI：

  10.1021/jm701344b

文献信息

• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20010034445A1

  公开（公告）日：2001-10-25

  Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. 1

  式(I)的化合物被披露，它们是在治疗骨质疏松症中有用的维特龙蛋白受体拮抗剂。
• VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0895475A1

  公开（公告）日：1999-02-10
• EP0895475A4
  申请人：——

  公开号：EP0895475A4

  公开（公告）日：2000-08-23
• EP0906103A4
  申请人：——

  公开号：EP0906103A4

  公开（公告）日：1999-04-07
• US6159964A
  申请人：——

  公开号：US6159964A

  公开（公告）日：2000-12-12